Fig 1: Schematic illustration of chemotherapy resistance acquisition in glioma cells. Glioma cells treated with TMZ activate early response mechanisms that include increased stemness marker (PROM1), OXPHOS activity, and increased MAGMAS expression to facilitate protein trafficking into mitochondria. DNA damage response mechanisms are also activated to help repair alkylated DNA. In the later stages of TMZ resistance acquisition, MGMT levels are elevated to remove the alkylated O6-methylguanine from DNA, making glioma cells more resistant to TMZ. MAGMAS levels are sustained at higher levels in chemotherapy-resistant cells with reprogrammed mitochondria, providing increased protein-trafficking capacity in mitochondria, which requires higher oxygen consumption and mitigates ROS toxicity. [Created in BioRender. Lepe, J. (2026) https://BioRender.com/ilvryag].
Fig 2: Pharmacologic MAGMAS inhibition by BT9 reduces protein trafficking into the mitochondria and increases oxidative stress in glioma lines U-251 MG, T98G, and D-54 MG. A, U-251 MG and D-54 MG were treated with 10 μmol/L BT9 for 24 hours. Mitochondrial lysates were collected, and protein levels of LONP1, ACO2, cytochrome C, COXIV, and TIM23 were assessed by Western blot. TIM23 was used as a loading control. B, U-251 MG and T98G cells were treated with 5 μmol/L BT9 and 2.5 mmol/L of NAC for 24 hours and probed with MitoSOX Red. The median fluorescence intensity (MFI) was determined by flow cytometry (n = 3 technical replicates). C, U-251 MG cells were exposed to 5.6 μmol/L BT9 ± 2.5 mmol/L NAC for 3 days. Cells were then stained with Annexin V/PI and analyzed by flow cytometry to assess early and late apoptosis. Early and late apoptosis events observed for the vehicle were 13%, 5.9% for the NAC control, 30.7% for the BT9-treated cells, and 13.6% for the BT9 and NAC-treated cells. Data representative of one experiment. Data are shown as the mean ± SD; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Fig 3: MAGMAS knockdown in GBM cells increases sensitivity to TMZ, radiation, and TTFs. A, Western blot analysis of MAGMAS protein levels in mitochondrial lysates from U-251 MG and T98G cells lentiviral transduced with either scramble control or shPAM16. TIM23 was used as a loading control for each sample. B,MGMT mRNA expression was quantified by qPCR in U-251 MG, T98G, and G12 scramble and shPAM16 cell lines. C, Whole cell lysates harvested from T98G scramble and sh1 cells probed with anti-MGMT (bottom bands) and Β-actin (top bands) as a loading control. Membrane is a duplicate of Supplementary Fig. S3D. Only T98G cells had detectable MGMT at the protein level which is highlighted here. D,PAM16 knockdown U-251 MG cells were treated with 24 μmol/L TMZ for 5 days, and the percent of PI+ cells were determined by flow cytometry (n = 4). E, Cellular ROS measured from U-251 MG, T98G, and G12 PAM16 knockdown cells with stained with CellROX and analyzed by flow cytometry (n = 4). Statistical analyses were done with unpaired t test, mean ± SD. F, Representative images of clonogenic assay plates and (G) quantification of surviving fraction of U-251 MG and T98G scramble control and PAM16 knockdown cells exposed to 0 to 6 Gy of radiation. Colonies were counted manually. Statistical analyses were performed using the mixed-effects model, Sidak multiple comparisons test, P < 0.05, mean with ± SD. MFI, median fluorescence intensity. H, U-251 MG and T98G scramble control and PAM16 knockdown cells were exposed to 200 Hz TTFs for 3 days. Cell viability was assessed by quantifying the percent of PI+ cells using flow cytometry. Significance was determined using a two-way ANOVA, Sidak multiple comparisons test, P < 0.05. I, Timeline and experimental design of the G12-Luc orthotopic xenograft model. Scramble + vehicle: n = 5; Scramble + TMZ; n = 5; Sh1 + vehicle: n = 5; Sh1 + TMZ: n = 5. J, Kaplan–Meier curve depicting survival of PAM16 knockdown transduced G12-Luc orthotopic xenograft mouse model. K, Summary of bioluminescence imaging of mice from all treatment groups (photons/s) from different time points of the study. L, The change in body weights of mice was measured at different time points throughout the study. Log-rank P values, Scrbl. vehicle vs. Sh1 vehicle P = 0.0017, Scrbl. vehicle vs. Scrbl. TMZ P = 0.0017, Scrbl. vehicle vs. Sh1 TMZ P = 0.0017, Scrbl. TMZ vs. Sh1 vehicle P = 0.0021, Scrbl. TMZ vs. Sh1 TMZ P= 0.0018, and Sh1 vehicle vs. Sh1 TMZ P = 0.0021. Data are shown as the mean ± SD; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. [I, Created in BioRender. Lepe, J. (2026) https://BioRender.com/wvy3h4p].
Fig 4: MAGMAS is differentially expressed in newly diagnosed vs. recurrent GBM patient-derived tumor specimens and TMZ-resistant glioma lines. A,PAM16 mRNA expression in IDH1 wild-type newly diagnosed and recurrent GBM tumor samples from the CGGA and TCGA datasets. Two-tailed unpaired t test statistical analyses was performed. B, Correlation between PAM16 and MGMT mRNA expression in primary GBM patient tumor samples. Pearson correlation, CGGA, R = 0.7869, P < 0.0001; TCGA, R = 0.2773, P < 0.0001. qPCR analysis of PAM16 in (C) U-251 MG S, TR, and OTR and (D) D-54 MG S, TR, and OTR lines. U-251 MG S and T98 cells treated with (E) 1,000 μmol/L TMZ, (F) 30 mmol/L DCA (U-251 MG S), or 34 mmol/L DCA (T98G). RNA was collected at 0 days (vehicle control) and 1-, 2-, and 3-day time points, and qPCR analysis of PAM16 was performed. One-way ANOVA, post hoc Tukey, P < 0.05. qPCR analysis of PAM16 expression in (G) U-251 MG S, (H) D-54 MG S, and (I) T98G cells cultured in GSC media. Cells were collected at 9 and 30 days, and PAM16 expression was compared with cells grown in serum control media. One-way ANOVA, post hoc Tukey, multiple comparisons, P < 0.05. J, Flow cytometry analysis of CD133 expression of D-54 MG cells at 0, 9, and 30 days cultured in GSC media for dedifferentiation. On 30 days of dedifferentiation, (K) U-251 MG and (L) D-54 MG were collected and treated with graded doses of TMZ for 5 days; cell viability was assessed by MTT. All data are shown as the mean ± SD; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Supplier Page from OriGene Technologies for PAM16 Human shRNA Plasmid Kit (Locus ID 51025)